Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 14, 2024 (Event Date: April 16, 2024; Closing Date: April 18, 2024)
Context: The Company entered into a Material Definitive Agreement to conduct a public offering of Common Stock Units and Pre-Funded Warrant Units to raise capital.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6.077 million.
- Offering Price: $0.40 per Common Stock Unit or Pre-Funded Warrant Unit (PFW Unit).
- Securities Issued:
- 13,232,500 Common Stock Units.
- 1,965,000 PFW Units.
- Warrant Exercise Price: $0.60 per share for Common Warrants included in the units.
- Debt Repayment: Proceeds were used to pay off convertible promissory notes totaling $1,600,000 ($1,500,000 and $100,000).
- Placement Agent Fees:
- Cash fee: 8.0% of aggregate gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Expense reimbursement: Up to $125,000.
- Warrants issued to agent: 759,875 shares at $0.66 exercise price.
Material Changes and Agreements
The filing details a significant capital raise and associated corporate actions:
- Reverse Stock Split: The Company agreed to hold a stockholder meeting within 75 days of the offering closing to approve a reverse stock split. Officers and directors have entered into voting agreements to support this measure.
- Warrant Structure: The offering includes complex warrant structures (Series A, B, B-1, C, C-1) with varying expiration dates (ranging from 4 months to 5 years) and immediate exercisability for Series A, B, and C warrants.
- Debt Conversion: A specific investor participated in the offering to convert outstanding convertible promissory notes into equity, eliminating $1.6 million in debt obligations.
Outlook, Risks, and Management Commentary
- Regulatory Disclosure: The Company issued a press release on April 19, 2024, announcing the closing of the $6.1 million offering (Item 7.01).
- Shareholder Action Required: The reverse stock split is contingent upon shareholder approval at a meeting to be held no later than 75 days post-closing.
- Warrant Adjustments: Warrant exercise prices are subject to adjustment in the event of a reverse stock split, potentially reducing the price to 90% of the lowest VWAP following the split.
- Financial Statements: This 8-K does not contain audited financial statements, revenue, profit, or cash flow data for a reporting period; it focuses solely on the transaction.
Investor Verification Checklist
- Verify the exact ratio of the proposed reverse stock split once the Board determines it.
- Confirm the net proceeds after deducting the 8.0% placement fee, 1.0% management fee, and up to $125,000 in expenses.
- Review the specific terms of the Series B and Series C warrants, which have shorter expiration periods (12 months and 4 months, respectively) compared to Series A.
- Monitor the upcoming stockholder meeting date for the vote on the reverse stock split.
- Check subsequent filings for the updated capitalization table reflecting the new shares and warrants issued.